

# Nonalcoholic Fatty Liver Disease Cirrhosis: A Review of Clinical Presentation, Diagnosis, Management, and Prog

Canadian Journal of Gastroenterology and Hepatology

2018, 1-8

DOI: [10.1155/2018/2784537](https://doi.org/10.1155/2018/2784537)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment. <i>Hormones</i> , 2018, 17, 573-579.	0.9	6
2	Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis. <i>Hepatology International</i> , 2019, 13, 757-765.	1.9	32
3	Lipid-lowering and antioxidative effects of <i>Apium graveolens</i> L. root flavonoid extracts. <i>RSC Advances</i> , 2019, 9, 26757-26767.	1.7	7
4	Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Nonalcoholic Fatty Liver Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 604.	1.6	16
5	The grade of nonalcoholic fatty liver disease is an independent risk factor for gallstone disease. <i>Medicine (United States)</i> , 2019, 98, e16018.	0.4	16
6	Physical activity can reduce the prevalence of gallstone disease among males. <i>Medicine (United States)</i> , 2019, 98, e16018.	0.4	16
7	Water Extract of <i>Artemisia annua</i> L. Exhibits Hepatoprotective Effects Through Improvement of Lipid Accumulation and Oxidative Stress-Induced Cytotoxicity. <i>Journal of Medicinal Food</i> , 2020, 23, 1312-1322.	0.8	6
8	Innovative strategies for reducing the burden of chronic liver disease. <i>British Journal of Nursing</i> , 2020, 29, S4-S9.	0.3	1
9	The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110785.	2.5	80
10	NLRP3 sparks the Greek fire in the war against lipid-related diseases. <i>Obesity Reviews</i> , 2020, 21, e13045.	3.1	6
11	Seroprevalence and factors associated with hepatitis B virus infection in blood donors in Ethiopia: a systematic review and meta-analysis. <i>Archives of Virology</i> , 2020, 165, 1039-1048.	0.9	5
12	Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 31-31.	1.5	25
13	NAFLD Preclinical Models: More than a Handful, Less of a Concern?. <i>Biomedicines</i> , 2020, 8, 28.	1.4	33
14	Influencia de los factores socioeconómicos y culturales en la etiología de la cirrosis hepática. <i>Revista De Gastroenterología De México</i> , 2021, 86, 28-35.	0.4	5
15	Influence of socioeconomic and cultural factors in the etiology of cirrhosis of the liver. <i>Revista De Gastroenterología De México (English Edition)</i> , 2021, 86, 28-35.	0.1	2
16	Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 4-4.	1.5	45
17	Gut Microbiome and Liver Cancer. <i>Physiology in Health and Disease</i> , 2021, , 199-255.	0.2	0
18	Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 817-827.	1.0	11

#	ARTICLE	IF	CITATIONS
19	Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 1667-1675.	0.2	27
20	Limits of Fat Quantification in the Presence of Iron Overload. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 54, 1166-1174.	1.9	10
21	Thrombin Generation in Chronic Liver Diseases—A Pilot Study. <i>Healthcare (Switzerland)</i> , 2021, 9, 550.	1.0	2
22	Nano-encapsulation of hydroxytyrosol into formulated nanogels improves therapeutic effects against hepatic steatosis: An in vitro study. <i>Materials Science and Engineering C</i> , 2021, 124, 112080.	3.8	12
23	Chronic Liver Disease Increases Mortality Following Pancreatoduodenectomy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2521.	1.0	3
24	Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. <i>Clinical Epigenetics</i> , 2021, 13, 152.	1.8	25
25	Ethanol Extract of <i>Liriope platyphylla</i> Root Attenuates Non-Alcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice via Regulation of Lipogenesis and Lipid Uptake. <i>Nutrients</i> , 2021, 13, 3338.	1.7	10
26	Non-alcoholic fatty liver disease - a look at diagnostic prospects. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 62-67.	0.1	0
27	THE EFFECT OF COMPREHENSIVE TREATMENT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH PREDIABETES ON THE LIPID PROFILE. <i>WiadomoÅci Lekarskie</i> , 2021, 74, 957-960.	0.1	0
28	Genetic defects of autophagy linked to disease. <i>Progress in Molecular Biology and Translational Science</i> , 2020, 172, 293-323.	0.9	10
29	Serum Marker Panels for Predicting Liver Fibrosis – An Update. , 2020, 41, 67-73.		6
30	Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. <i>Endocrinology and Metabolism</i> , 2021, 36, 1016-1028.	1.3	6
31	Recurrent NASH Post-liver Transplant: Implications and Treatment. <i>Current Hepatology Reports</i> , 2021, 20, 108.	0.4	0
32	Serum Biomarkers of Iron Status and Risk of Hepatocellular Carcinoma Development in Patients with Nonalcoholic Fatty Liver Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 230-235.	1.1	10
33	Coexisting Cirrhosis Worsens Inpatient Outcomes in Patients With Infective Endocarditis: A Cross-Sectional Analysis of the National Inpatient Sample 2013-2014. <i>Cureus</i> , 2020, 12, e11826.	0.2	0
34	THERAPEUTIC PLASMAPHERESIS IN A COMPLEX – TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS. <i>WiadomoÅci Lekarskie</i> , 2020, 73, 1454-1458.	0.1	4
35	Screening for Non-alcoholic Fatty Liver Disease in Current Practice. <i>Current Hepatology Reports</i> , 2021, 20, 128-134.	0.4	0
37	Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2021, 8, 814951.	1.2	8

#	ARTICLE	IF	CITATIONS
38	Lactiplantibacillus plantarum AR113 Exhibit Accelerated Liver Regeneration by Regulating Gut Microbiota and Plasma Glycerophospholipid. <i>Frontiers in Microbiology</i> , 2021, 12, 800470.	1.5	7
39	Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. <i>Metabolic Syndrome and Related Disorders</i> , 2022, , .	0.5	2
40	Features of modeling fatty liver disease in rats of different ages based on a high-calorie diet. <i>Obesity and Metabolism</i> , 2022, 18, 387-397.	0.4	2
41	Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 483-496.	4.5	49
42	The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. <i>Biomedicines</i> , 2021, 9, 1948.	1.4	4
43	Nutritional Assessment of Liver Cirrhosis Patients Visiting Public Hospital, Lahore. <i>Diet Factor</i> , 0, , 44-47.	0.0	0
44	Knowledge, attitude and practice of Gastroenterologists and hepatologists regarding vaccination in patients with chronic liver disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, , .	0.4	0
45	Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis. <i>Environmental Health Perspectives</i> , 2022, 130, 46001.	2.8	128
46	Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review. <i>Cureus</i> , 2022, , .	0.2	4
47	Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome in Women: Effects of Lifestyle Modifications. <i>Journal of Clinical Medicine</i> , 2022, 11, 2759.	1.0	4
48	MAFLD Versus NAFLD: Which Better Predicts the Risk of Atherosclerotic Cardiovascular Disease?. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4606-4608.	1.1	1
49	OBEZ SIÄ±ANLARDA SELENYUM VE N-ASETÄ°L SÄ°STEÄ°NÄ±MÄ°N FERTÄ°LÄ°TE/ Ä°NFERTÄ°LÄ°TE VE KARACÄ°Ä±ZERÄ°NE ETKÄ± KoÅŒman Ä±niversitesi TÄ±p Dergisi, 0, , .	0.2	0
50	A comprehensive review of coronary artery disease in patients with end-stage liver disease. <i>Transplantation Reviews</i> , 2022, 36, 100709.	1.2	4
51	La esteatohepatitis no alcohÃ³lica: una causa emergente de cirrosis en Colombia. <i>Revista Colombiana De Gastroenterologia</i> , 2022, 37, 136-144.	0.1	0
52	A potential link between plasma shortâ€chain fatty acids, TNFâ€ level and disease progression in nonâ€alcoholic fatty liver disease: A retrospective study. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	12
53	Association between Coronary Artery Plaque Progression and Liver Fibrosis Biomarkers in Population with Low Calcium Scores. <i>Nutrients</i> , 2022, 14, 3163.	1.7	2
54	Hepatic PEMT Expression Decreases with Increasing NAFLD Severity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9296.	1.8	14
55	Rare leptin in non-alcoholic fatty liver cirrhosis: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10293-10300.	0.3	0

#	ARTICLE	IF	CITATIONS
56	Liver Disease Among Mexican Americans Aged 67 Years and Older. <i>Journal of Primary Care and Community Health</i> , 2022, 13, 215013192211162.	1.0	0
58	Effectiveness of Lifestyle Interventions for Nonalcoholic Fatty Liver Disease Treatment. , 0, , .		1
59	Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2023, 12, 3589-3600.	1.3	5
60	Nonalcoholic fatty liver disease and diabetes. <i>World Journal of Diabetes</i> , 2022, 13, 668-682.	1.3	4
61	Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1622-1636.	0.8	6
62	Risk Prevention and Health Promotion for Non-Alcoholic Fatty Liver Diseases (NAFLD). <i>Livers</i> , 2022, 2, 264-282.	0.8	3
63	Design and synthesis of ER $\alpha$ agonists: Effectively reduce lipid accumulation. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	0
64	Towards Whole Health Toxicology: In-Silico Prediction of Diseases Sensitive to Multi-Chemical Exposures. <i>Toxics</i> , 2022, 10, 764.	1.6	2
65	Prevalence of Spontaneous Bacterial Peritonitis (SBP) in Hepatitis B (HBV), and Hepatitis C (HCV) Liver Cirrhosis: A Systematic Review and Meta-Analysis. <i>Healthcare (Switzerland)</i> , 2023, 11, 275.	1.0	2
66	The Link between NAFLD and Metabolic Syndrome. <i>Diagnostics</i> , 2023, 13, 614.	1.3	10
67	Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease. <i>Journal of Genetic Engineering and Biotechnology</i> , 2023, 21, 13.	1.5	0
68	Raman scattering-based optical sensing of chronic liver diseases. <i>Photodiagnosis and Photodynamic Therapy</i> , 2023, 42, 103505.	1.3	1
69	Does metabolic syndrome affect perioperative outcomes in patients undergoing robotic hepatectomy? A propensity score-matched analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 0, , .	1.3	0
70	High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease. <i>Cancer</i> , 2023, 129, 2341-2347.	2.0	2